In July, the US Food and Drug Administration (FDA) approved a new blood-based test to screen for colorectal cancer (CRC). The FDA's approval of Shield (Guardant Health) marks a notable achievement, as ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...

Screening for the second leading cause of cancer deaths just got a bit easier. The U.S. Food and Drug Administration (FDA) announced the approval of a new blood test for colorectal cancer (CRC).

A noninvasive colorectal cancer screening test that can be done at home could reduce the risk of colorectal cancer death by 33%, according to a new study. A noninvasive colorectal cancer screening ...

A next-generation multitarget stool DNA test, including assessments of DNA molecular markers and hemoglobin level, was developed to improve the performance of colorectal cancer screening, primarily ...

Credit: Guardant. The Shield blood test for colorectal cancer screening is a qualitative in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood ...

Colorectal cancer is the third most diagnosed cancer in adults in the United States. Early detection could prevent more than 90% of colorectal cancer–related deaths, yet more than one third of the ...

Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...